摘要
目的:探讨CYP2C9和VKORC1基因多态性对机械瓣膜置换妊娠患者华法林稳定剂量的影响,结合非遗传因素建立妊娠患者的华法林给药模型。方法:纳入68例使用华法林的妊娠患者,应用PCR-芯片法检测CYP2C9和VKORC1基因多态性,收集患者病理生理资料,采用多元线性逐步回归法分析遗传因素和非遗传因素对妊娠患者华法林剂量的影响并构建华法林个体化剂量给药模型。结果:CYP2C9和VKORC1基因多态性对妊娠患者华法林稳定剂量有显著影响,CYP2C9、VKORC1和体质量可解释44. 6%的华法林剂量的个体差异。结论:遗传因素是影响妊娠患者华法林稳定剂量变异的重要因素,CYP2C9和VKORC1基因多态性检测适合应用于妊娠患者。
Objective： To explore the effects of genetic factors and non-genetic factors on warfarin dosage in pregnant women after heart valve replacement. Methods： Totally 68 pregnant women were treated with warfarin throughout pregnancy. PCR-chip method was used to detect the polymorphism of CYP2C9 and VKORC1 gene,and the clinical data were collected. The effects of genetic factors and non-genetic factors on stable dosage of warfarin were statistically analyzed. Results： CYP2C9,VKORCl genotypes and weight had significant effects on warfarin dosage. The three variables could explain 44. 6% of warfarin individual differences. Conclusion： Genetic factors have significant effect on warfarin dosage in pregnant patients,so the detection of genetic polymorphism of CYP2C9 and VKORCl can be applied to individualize warfarin dosage in pregnant patients with heart valve replacement.
作者
张进华
吴健梅
曹华
Zhang Jinhua;Wu Jianmei;Cao Hua(Department of Pharmacy,Fujian Medical University Union Hospital,Fuzhou 350001,China;Department of Cardiovascular Surgery,Fujian Medical University Union Hospital;Fujian Provincial Maternity and Child Heath Hospital)
出处
《中国药师》
CAS
2018年第10期1790-1793,共4页
China Pharmacist
基金
福建省科技计划引导性项目(编号:2015Y0020)
上海百傲科技股份有限公司资助项目
